Sign up for our daily briefing

Make your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Catch up on the day's biggest business stories

Subscribe to Axios Closer for insights into the day’s business news and trends and why they matter

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Stay on top of the latest market trends

Subscribe to Axios Markets for the latest market trends and economic insights. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Sports news worthy of your time

Binge on the stats and stories that drive the sports world with Axios Sports. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Tech news worthy of your time

Get our smart take on technology from the Valley and D.C. with Axios Login. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Get the inside stories

Get an insider's guide to the new White House with Axios Sneak Peek. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Denver news?

Get a daily digest of the most important stories affecting your hometown with Axios Denver

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Des Moines news?

Get a daily digest of the most important stories affecting your hometown with Axios Des Moines

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Twin Cities news?

Get a daily digest of the most important stories affecting your hometown with Axios Twin Cities

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Tampa Bay news?

Get a daily digest of the most important stories affecting your hometown with Axios Tampa Bay

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Charlotte news?

Get a daily digest of the most important stories affecting your hometown with Axios Charlotte

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Illustration: Eniola Odetunde/Axios

Scientists are racing to learn more about the damage the novel coronavirus can do to the heart, lungs and brain.

Why it matters: It’s becoming increasingly clear that some patients struggle with its health consequences — and costs — far longer than a few weeks.

The big picture: The virus can have a severe impact on the lungs, as you might expect. Pneumonia associated with the disease can damage air sacs in the lungs, and the resulting scar tissue can cause long-term breathing problems.

  • But researchers conducting autopsies have also found evidence of the virus in parts of the brain, kidneys, gastrointestinal tract and in the cells that line blood vessels, the Washington Post has reported. They’ve also found clotting in many organs.
  • And problems with the vascular system — body’s network of blood vessels — ”could unleash a global surge in vascular diseases, from stroke and atherosclerosis to myocarditis and heart attack,” William Li and Andrew von Eschenbach wrote in a recent WaPo op-ed. Li is the president of the Angiogenesis Foundation, and von Eschenbach is a former Food and Drug Administration commissioner.

One of the most attention-grabbing effects of the virus is its link to myocarditis, particularly because of concerns about the dangers the heart disease poses to athletes.

  • One particularly alarming study, conducted in Germany, found that 78% of people who had recovered from the coronavirus had heart abnormalities that could be detected on an MRI two months later, including many who hadn’t been hospitalized. Around 60% had signs of myocarditis.
  • But it’s hard to attach meaning to these findings yet, as The Atlantic’s Ed Yong recently reported. Many people have myocarditis and are fine; others can have severe complications, including health failure and death.
  • “How do the numbers compare to other respiratory viruses? Will COVID-19 patients with myocarditis recover fully, or will some have long-term problems? Is this virus doing something strange, or are researchers just studying it more intensely than other viral infections? For now, it’s difficult to say,” Yong writes.

Coronavirus patients frequently report neurological symptoms — including scary ones like stroke, brain hemorrhage and memory loss — and a recent study found evidence that the virus can invade brain cells, the New York Times writes. The study hadn’t yet been peer-reviewed.

  • Between 40% and 60% of hospitalized coronavirus patients have neurological and psychiatric symptoms. But that doesn’t necessarily mean that the virus has invaded their brain cells, Robert Stevens, a neurologist at Johns Hopkins University, told the NYT.
  • Patients with neurological symptoms aren’t always those who have been seriously ill. “We’ve seen this group of younger people without conventional risk factors who are having strokes, and patients having acute changes in mental status that are not otherwise explained,” Benedict Michael, a neurologist at the University of Liverpool, UK, told Nature.
  • Autopsies have also found extensive brain damage due to oxygen deprivation, which raises the question of “what happens to people who survive covid,” as Isaac Solomon, a neuropathologist at Brigham and Women’s Hospital in Boston, told the Post.

Between the lines: It’s unclear whether the virus itself causes organ damage, or whether it’s a result of the body’s immune response — or both.

  • That matters for how a patients’ symptoms are treated. “It’s pointless giving the antivirals to someone if the virus is gone, and it’s risky giving anti-inflammatories to someone who’s got a virus in their brain,” Michael told Nature.

The bottom line: Even if we manage to get the coronavirus under control, whether that’s through a vaccine or behavior modification, we’re probably going to be dealing with its effects for a long time.

Go deeper

Fauci says COVID variants threaten some treatments more than vaccines

Illustration: Aïda Amer/Axios

The COVID-19 variants first detected in the U.K. and South Africa and now circulating globally aren't a current threat to the effectiveness of the first vaccines, but mutations will be closely monitored because "they could be an issue," NIAID director Anthony Fauci tells Axios.

The big picture: Vaccinations are underway, albeit with a slow start. The get-back-to-normal-goal depends on reaching 70%–85% herd immunity in the population, Fauci says. While there are some concerns the mutations might circumvent the vaccines, he says they pose more of a problem for certain treatments than for vaccines.

Jan 7, 2021 - Health

China's Sinovac coronavirus vaccine 78% effective in Brazil trials

São Paulo Gov. Joao Doria holds a box of the CoronaVac vaccine during a press conference. Photo: Alexandre Schneider via Getty Images

A coronavirus vaccine produced by Chinese company Sinovac is 78% effective, Brazil officials announced Thursday.

Why it matters: Regulators in other countries are closely following the Phase 3 trials in Brazil. If the vaccine is approved for use, it could help fill a gap in access to coronavirus vaccines for many low- and middle-income countries.

Fauci says vaccine rollout’s "bumps and hiccups” won’t last long

Photo illustration: Eniola Odetunde/Axios. Photos: the Washington Post, Pool/Getty Images

Despite the slow roll out of vaccines so far, NIAID director Anthony Fauci says the COVID-19 vaccination campaign will ramp up fast enough that Americans should see "a degree of normality in the fall."

Driving the news: President-elect Biden is planning a program that will have "much more interaction between the federal government and the states than there are right now" in order to reach his goal of 1 million vaccines a day for 100 days, Fauci tells Axios.